News | Clinical Decision Support | October 16, 2017

Appropriate Use Criteria Published for Valvular Heart Disease Imaging Tests

Document provides guidance to physicians for diagnosing, managing patients

Appropriate Use Criteria Published for Valvular Heart Disease Imaging Tests

October 16, 2017 — The American College of Cardiology (ACC), along with several partnering societies, recently released appropriate use criteria addressing the evaluation and use of multimodality imaging in the diagnosis and management of valvular heart disease.

Initial diagnosis and subsequent follow-up for valvular heart disease frequently rely on imaging with more than one imaging modality. Rapidly evolving less-invasive and transcatheter treatment options have fueled the need for precise preprocedural and intraprocedural anatomic and functional imaging.

“As imaging technologies and clinical applications continue to advance, the healthcare community must understand how best to incorporate these technologies into daily clinical care and how to choose between new and established imaging technologies,” said John U. Doherty, M.D., professor of medicine at Thomas Jefferson University and chair of the writing committee.

This document addresses the appropriate use of multiple cardiac imaging modalities available to clinicians in the evaluation of patients with valvular heart disease. It covers the spectrum of patients with valvular heart disease — from patients with no symptoms who are suspected of having valvular heart disease, to patients with signs and symptoms ranging from mild to severe. A standardized approach was used to create different categories of indications with the goal of capturing actual real-world clinical scenarios. These clinical scenarios, or indications, were developed by the writing committee to cover established and emerging treatment approaches for valvular heart disease. An independent rating panel scored the clinical scenarios, assessing whether the use of an imaging test for each indication fell into one of the following categories: Appropriate, May Be Appropriate or Rarely Appropriate.

The goal of this document is to identify all imaging tests that are considered reasonable for a given clinical indication. Therefore, the testing modalities were rated for their level of appropriateness specific to clinical scenarios rather than a forced rank order comparison against other testing modalities.

According to the writing committee, the indications are, at times, intended to be broad to cover an array of cardiovascular signs and symptoms and to account for the ordering physician’s best judgment regarding the presence of cardiovascular abnormalities. However, there are likely clinical scenarios that are not covered in the document.

The ACC/AATS/AHA/ASE/ASNC/HRS/SCAI/SCCT/SCMR/STS 2017 Appropriate Use Criteria for Multimodality Imaging in Valvular Heart Disease is published online in the Journal of the American College of Cardiology, the Journal of the American Society of Echocardiography, the Journal of Nuclear Cardiology and the Journal of Thoracic and Cardiovascular Surgery. This document is the first of two companion appropriate use criteria documents developed by these partnering societies. The second companion document, addressing multimodality imaging in structural heart disease, will publish at a later date.

For more information: www.acc.org

Related Content

HHS Releases Second Edition of Physical Activity Guidelines for Americans
News | Cardiac Diagnostics | November 14, 2018
The U.S. Department of Health and Human Services (HHS) released the second edition of the Physical Activity Guidelines...
ACC and AHA Release Updated Cholesterol Guidelines for 2018. #AHA18 #AHA2018
Feature | Cardiac Diagnostics | November 13, 2018
November 13, 2018 — New cholesterol guidelines from the American Heart Association (AHA) and the American College of
AMI READMITS Score Predicts Heart Attack Patients at High Readmission Risk
News | Cardiac Diagnostics | October 09, 2018
Tracking just seven factors of heart attack patients when they are first admitted to the hospital can help flag those...
Siemens Healthineers Showcases New In Vivo and In Vitro Cardiovascular Solutions at TCT 2018
News | Cardiac Diagnostics | September 21, 2018
At the 2018 Transcatheter Cardiovascular Therapeutics (TCT) conference, Sept. 21-25 in San Diego, Siemens Healthineers...
Weight Loss Drug Does Not Increase Cardiovascular Events
News | Cardiac Diagnostics | August 31, 2018
A weight loss drug does not increase cardiovascular events, according to late breaking results from the CAMELLIA-TIMI...
Acarix Presents CADScor System at ESC 2018
News | Cardiac Diagnostics | August 27, 2018
Acarix AB’s ultra-sensitive acoustic CADScor System for coronary artery disease risk assessment will be on display at...
NIH Ending Funding for Moderate Alcohol and Cardiovascular Health Trial
News | Cardiac Diagnostics | August 24, 2018
The National Institutes of Health announced in June it plans to end funding to the Moderate Alcohol and Cardiovascular...
Study Shows Multiple Benefits of Patient-to-Patient Connectivity in Familial Chylomicronemia Syndrome
News | Cardiac Diagnostics | August 07, 2018
Akcea Therapeutics Inc., an affiliate of Ionis Pharmaceuticals Inc., announced the publication of results from the...
Being Overweight May Change Young Adults' Heart Structure, Function
News | Cardiac Diagnostics | August 03, 2018
Even as a young adult, being overweight may cause higher blood pressure and thicken heart muscle, setting the stage for...
Overlay Init